Zevra Miplyffa CHMP Rejected for Niemann-Pick Type C

Zevra Therapeutics (ZVRA) announced on July 24, 2026 that the EMA’s Committee for Medicinal Products for Human Use adopted a negative opinion on the Marketing Authorization Application for Miplyffa (arimoclomol) for the treatment of Niemann-Pick disease type C, a rare progressive neurodegenerative disorder. Zevra plans to request a re-examination of the decision.

ZVRA closed at $9.53 on July 24, with a market cap near $563 million. The stock has been volatile on regulatory news, with a 12.5% one-day move after recent patent-listing news and a 3.9% decline after a leadership update, but the CHMP negative opinion had not yet been reflected in the close as of the announcement.

The US-EU regulatory divide

The FDA approved Miplyffa on September 20, 2024 as the first treatment for NPC, in combination with miglustat. The approval followed a favorable 11-5 vote from the FDA’s Genetic Metabolic Diseases Advisory Committee on August 2, 2024. The US filing was a resubmission after an earlier rejection, with a PDUFA date that moved from June 21 to September 21, 2024.

The CHMP reviewed the same data and reached the opposite conclusion. The FDA approval was based on the R4DNPCCSS severity scale showing disease progression halted: Miplyffa plus miglustat showed a -0.2 point change versus +1.9 for miglustat alone. The EMA has not published detailed reasoning for the negative opinion yet, but European regulators generally require stronger evidence for rare disease approvals than the FDA’s accelerated approval pathway allows.

What NPC is

Niemann-Pick disease type C is an ultra-rare, progressive, and neurodegenerative lysosomal storage disorder caused by mutations in the NPC1 or NPC2 genes. The body cannot transport cholesterol and other lipids within cells, leading to accumulation in tissues including the brain. Patients lose independence due to physical and cognitive limitations, with neurological impairments in speech, cognition, swallowing, ambulation, and fine motor skills. Disease progression is irreversible. The US prevalence is approximately 900 patients, with roughly a third diagnosed.

Why this matters

For Zevra, the EU approval was always a secondary concern given the ultra-rare nature of NPC. EU revenue would have been modest. But the negative opinion is a credibility signal investors should weigh. When the FDA and EMA disagree on the same dataset, it raises questions about the strength of the evidence that supported the US approval. The re-examination process will take 6 to 12 months, during which EU patients have no access to arimoclomol outside of expanded access programs.

What to watch

Zevra is commercializing Miplyffa in the US, where it has exclusivity. The US revenue trajectory is the primary value driver for the stock. The CHMP re-examination request will include a detailed explanation of the company’s position, but the base rate for overturned negative opinions is low. Watch for the re-examination outcome and any additional real-world data Zevra generates from its US launch to strengthen the EU case. For context on how regulatory divergence between the FDA and other agencies affects drug approvals, see our guide to PDUFA dates.

Sources: Zevra press release via StockTitan, EMA CHMP meeting highlights July 20-23, 2026.

What It Means for the Trade

With roughly 900 US NPC patients and EU revenue always a rounding error, the CHMP opinion is a sentiment event, not a cash-flow event — but sentiment events in small caps move real money, and this one cuts against a credibility narrative Zevra has been building since the 2024 US approval. The trade-relevant question is what the negative opinion does to the US launch’s perceived durability. The FDA approved on a severity-scale endpoint showing halted progression (-0.2 versus +1.9 for miglustat alone); if European reviewers found that same dataset unconvincing, the resilience of the US label to future scrutiny becomes a fair topic for investor diligence. The mechanics are slow from here: re-examination runs 6-12 months, overturn rates on negative CHMP opinions are historically low, and there is no catalyst in that window beyond the re-examination outcome itself. The US commercial trajectory — prescription growth, payer coverage, real-world outcomes data — remains the only durable driver for a $563 million market cap.

Mechanism and Market Context

NPC1 or NPC2 mutations disable intracellular lipid trafficking, letting cholesterol and other lipids accumulate in lysosomes and, critically, in the brain, where the neurodegeneration that defines the disease occurs. Miplyffa (arimoclomol) takes a pharmacological-chaperone-style approach to cellular stress rather than replacing the broken transporter: it amplifies the heat-shock response, boosting molecular chaperones that help proteins fold and cells survive proteotoxic stress. That indirect mechanism is why the evidence base is a severity scale rather than a biomarker of lipid clearance, and why regulators can read the same numbers differently — the FDA accepted clinical-functional stabilization under its accelerated-approval framework, while the CHMP applies a stricter standard for what counts as benefit in a progressive neurodegenerative disease. The FDA-EMA divergence on rare-disease approvals is a recurring industry pattern, not a Zevra-specific anomaly, and the miglustat-combination design gives European reviewers a confound the US pathway absorbed.

Risks and What Could Go Wrong

1. The re-examination likely fails — historical overturn rates are low — locking Zevra out of the EU market for the foreseeable future.
2. A high-profile regulatory rejection of the US-approved dataset can invite prescriber and payer hesitation stateside, however unfairly.
3. With the stock already volatile on secondary news flows, the absence of positive catalysts for 6-12 months leaves the chart exposed to drift.